Key facts
- This page summarizes Lance A. Berry's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 May 2024, 17:30.
Lance A. Berry - 21 May 2024 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)
- Reporting relationship
- Director
- Issuer ticker
- TMCI
- Reported as of
- 21 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 May 2024, 17:30:14 UTC
- Prior SEC filing
- 26 Feb 2024
- Next SEC filing
- 24 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Taylor as Attorney-in-fact for Lance A. Berry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lance A. Berry filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 22 May 2024.
Change
- Previous filing in this sequence was filed on 26 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMCI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,091
- Change %
- +270%
- Price
- $0.000000
- Shares after
- 20,676
- Date
- 21 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMCI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +33,260
- Change %
- Price
- $0.000000
- Shares after
- 33,260
- Date
- 21 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,260
- Exercise price
- $4.97
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 21, 2025 or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.
Footnote F2
Includes 18,788 restricted stock units.
Footnote F3
The stock option will vest in 12 substantially equal monthly installments, commencing on June 21, 2024, such that the stock option will be fully vested and exercisable on the earlier of (a) May 21, 2025, or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date.